Axsome Therapeutics Inc (AXSM) is now in the Undervalued zone, suggesting that its current forward PS ratio of 10.38 is considered Undervalued compared with the five-year average of -23.45. The fair price of Axsome Therapeutics Inc (AXSM) is between 228.89 to 249.53 according to relative valuation method. Compared to the current price of 166.38 USD , Axsome Therapeutics Inc By Undervalued By 27.31%.

Relative Value

Fair Zone

228.89-249.53

Current Price：166.38

27.31%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Axsome Therapeutics Inc (AXSM) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Axsome Therapeutics Inc (AXSM) has a current Price-to-Book (P/B) ratio of 121.93. Compared to its 3-year average P/B ratio of 48.32, the current P/B ratio is approximately 152.33% higher. Relative to its 5-year average P/B ratio of 49.37, the current P/B ratio is about 146.96% higher. Axsome Therapeutics Inc (AXSM) has a Forward Free Cash Flow (FCF) yield of approximately -1.13%. Compared to its 3-year average FCF yield of -3.26%, the current FCF yield is approximately -65.51% lower. Relative to its 5-year average FCF yield of -4.61%, the current FCF yield is about -75.57% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for AXSM competitors is 36.90, providing a benchmark for relative valuation. Axsome Therapeutics Inc Corp (AXSM.O) exhibits a P/S ratio of 10.38, which is -71.88% above the industry average. Given its robust revenue growth of 65.03%, this premium appears sustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of AXSM increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of AXSM in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is AXSM currently overvalued or undervalued?

Axsome Therapeutics Inc (AXSM) is now in the Undervalued zone, suggesting that its current forward PS ratio of 10.38 is considered Undervalued compared with the five-year average of -23.45. The fair price of Axsome Therapeutics Inc (AXSM) is between 228.89 to 249.53 according to relative valuation method. Compared to the current price of 166.38 USD, Axsome Therapeutics Inc is Undervalued By 27.31%.

What is Axsome Therapeutics Inc (AXSM) fair value?

AXSM's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Axsome Therapeutics Inc (AXSM) is between 228.89 to 249.53 according to relative valuation method.

How does AXSM's valuation metrics compare to the industry average?

The average P/S ratio for AXSM's competitors is 36.90, providing a benchmark for relative valuation. Axsome Therapeutics Inc Corp (AXSM) exhibits a P/S ratio of 10.38, which is -71.88% above the industry average. Given its robust revenue growth of 65.03%, this premium appears sustainable.

What is the current P/B ratio for Axsome Therapeutics Inc (AXSM) as of Mar 03 2026?

As of Mar 03 2026, Axsome Therapeutics Inc (AXSM) has a P/B ratio of 121.93. This indicates that the market values AXSM at 121.93 times its book value.

What is the current FCF Yield for Axsome Therapeutics Inc (AXSM) as of Mar 03 2026?

As of Mar 03 2026, Axsome Therapeutics Inc (AXSM) has a FCF Yield of -1.13%. This means that for every dollar of Axsome Therapeutics Inc's market capitalization, the company generates -1.13 cents in free cash flow.

What is the current Forward P/E ratio for Axsome Therapeutics Inc (AXSM) as of Mar 03 2026?

As of Mar 03 2026, Axsome Therapeutics Inc (AXSM) has a Forward P/E ratio of -122.77. This means the market is willing to pay $-122.77 for every dollar of Axsome Therapeutics Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Axsome Therapeutics Inc (AXSM) as of Mar 03 2026?

As of Mar 03 2026, Axsome Therapeutics Inc (AXSM) has a Forward P/S ratio of 10.38. This means the market is valuing AXSM at $10.38 for every dollar of expected revenue over the next 12 months.

AXSM Valuation